Citius Pharmaceuticals, Inc.
CTXR
$0.56
-$0.03-5.65%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -57.73% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -57.73% | -- | |||
| Cost of Revenue | -58.32% | -- | |||
| Gross Profit | -57.58% | -- | |||
| SG&A Expenses | 201.76% | 47.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 159.42% | 46.85% | |||
| Operating Income | -260.82% | -0.10% | |||
| Income Before Tax | -210.43% | -7.67% | |||
| Income Tax Expenses | -187.51% | 0.00% | |||
| Earnings from Continuing Operations | -199.23% | -7.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 486.36% | 49.55% | |||
| Net Income | -158.26% | -3.29% | |||
| EBIT | -260.82% | -0.10% | |||
| EBITDA | -265.26% | 6.69% | |||
| EPS Basic | -148.12% | 17.37% | |||
| Normalized Basic EPS | -179.71% | 26.02% | |||
| EPS Diluted | -148.12% | 17.37% | |||
| Normalized Diluted EPS | -179.71% | 26.02% | |||
| Average Basic Shares Outstanding | 4.10% | 24.97% | |||
| Average Diluted Shares Outstanding | 4.10% | 24.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||